A long-acting biologic with transmucosal transport properties that arrest SARS-CoV-2 virus variants

When the COVID-19 pandemic first started, no effective anti-viral drugs were available to fight the disease. However, in record time, so-called monoclonal antibodies were developed as a lifesaving treatment. Now, three years later, none of the approved antibodies work effectively against the new SARS-CoV-2 virus variants due to mutations that alter their spike protein.